Teijaro Lab
@Teijaro_Lab
Followers
386
Following
78
Media
10
Statuses
51
Chronic viral infections, Chemical Immunology, and immuno-oncology @ScrippsResearch
La Jolla, San Diego
Joined March 2018
RT @LabWaggoner: Dysregulated ISG15 production and signaling during persistent LCMV infection drives lethal immune pathology, representing….
0
4
0
Congrats to everyone involved. @andyjminn, @EJohnWherry, @divijmathew, @zakjerry1 and @Isa57569543. Two great complimentary studies that hopefully will catalyze better treatments for patients in need soon! 👏.
In two separate Science studies, researchers report that combining JAK inhibitors with checkpoint inhibitor immunotherapy enhances cancer patient response. Learn more ⬇️.📄: 📄: #SciencePerspective:
1
0
15
RT @NatureBiotech: JAK inhibitors enhance anti–PD-1 immunotherapy by modulating T cell exhaustion and inflammatory signaling, as shown in p….
0
23
0
Proud of my two post-docs on their Science paper demonstrating JAK inhibitors can promote better anti-tumor responses in combination with checkpoint immunotherapy. Well done Jerry and Isa as well as all the authors! Special thanks to Dr. Veronika Bachanova for running the trial!.
A new @ScienceMagazine study led by Prof. John Teijaro, PhD, found that combining ruxolitinib, an approved drug, with checkpoint inhibitors supercharged T-cell responses. This could transform #cancer treatment, especially for tough-to-treat cancers. More:
3
2
25
Pleased to see this one in print. What a journey with the parker lab @_chrisgparker_! Great example of merging chemical biology and immunology to generate an exciting tool to probe the immune response. Congrats to everyone involved and all the hard work!!.
1
3
21
RT @_chrisgparker_: Excited to share the final version in.@nchembio. Lots more mechanistic insights & characterization, including our inhib….
0
25
0
Humbled to be a part of this newest venture with great colleagues Ben Cravatt, Chris Parker and Stuart Schreiber. Looking forward to what lies ahead!.
Belharra Therapeutics is finally ready to rise out of stealth with $130 million in capital and a multi-year collaboration with Genentech.
1
1
19
Excited to share work with our lab and Parker lab @_chrisgparker_ on the development and characterization of the first Slc15a4 inhibitors.
0
2
16
Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy
0
0
3
RT @CellChemBiol: Check out the review by @_chrisgparker_ from @scrippsresearch on the integration #phenotypic #screening and #chemoproteom….
0
5
0
RT @scrippsresearch: Congratulations to @EOSaphire on being newly appointed as President and CEO @ljiresearch. A former graduate student an….
0
6
0
Merry Christmas and Happy Holidays from all of us in the Teijaro Lab!.
0
0
13
Great example of basic research at Scripps and the Calibr drug discovery engine coming together to advance medicines for human disease. Watch this space. Congrats to all involved!.
STING attack on #cancer! In work by @Teijaro_Lab & Lairson Lab, Scripps Research scientists discover a drug that can activate the immune-boosting protein STING. Efficacy against #melanoma shows its potential as a future #anticancer therapy @ScienceMagazine
0
0
7
Great day for the lab! Our collaborative work with Luke Larson's lab and Calibr came out today in Science! Congratulations to Vincent, Emily, Ying, and the whole team! We identified and characterized a novel, anti-tumor STING agonist, SR-717. Read it here:
8
12
57
0
2
11
Tour de force!.
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
0
2
10
RT @bxv_imm: Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
0
3
0
The latest story from our lab describing the detrimental effects of extracelluar ISG15 in the lungs during viral infection is on BioRxiv now! Congratulations to our postdoc Namir Shaabani, who is the first author! Check it out here:
1
4
28
RT @mmw_lmw: Wendy L Havran, 1955-2020 | With heavy hearts, we mourn the sudden passing of a very dear friend on January 20, 2020 | An exc….
0
4
0